Provisional approval for adolescent bivalent booster

Moderna’s bivalent Covid-19 vaccine (elasomeran and davesomeran) has been granted provisional approval for use as a booster in adolescents aged 12 years and older  The vaccine is the second targeting the Omicron BA.4 and BA.5 subvariants to get the green light from the Therapeutic Goods Administration (TGA), with Pfizer’s Comirnaty Bivalent Omicron BA.4/BA.5 jab being

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Perrottet pledges to fund pharmacist prescribing
Next PBS co-payment cut delivering savings: Butler